sellWeak cluster of 410b5-1 plan
Henry E. Pelish sold $614k of NUVL
Chief Scientific Officer at Nuvalent, Inc.. 7,645 shares at an average of $80.31, traded Jul 9, 2025, filed Jul 11, 2025.
Warning score
20Value
$614k
7,645 shares
Holdings after
60,956
-12% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +20Trade size$614k at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-095312, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,945 | $81.08 | $158k | 61,156 | Jul 11, 2025 |
| Jul 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -200 | $81.90 | $16k | 60,956 | Jul 11, 2025 |
| Jul 10, 2025 | MOption exercise Class A Common Stock10b5-1 | +182 | $18.93 | $3,445 | 61,138 | Jul 11, 2025 |
| Jul 10, 2025 | MOption exercise Class A Common Stock10b5-1 | +878 | $27.85 | $24k | 62,016 | Jul 11, 2025 |
| Jul 10, 2025 | MOption exercise Class A Common Stock10b5-1 | +4,440 | $29.33 | $130k | 66,456 | Jul 11, 2025 |
| Jul 10, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -5,260 | $79.94 | $420k | 61,196 | Jul 11, 2025 |
| Jul 10, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -240 | $80.92 | $19k | 60,956 | Jul 11, 2025 |
| Jul 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -182 | $0.00 | $0 | 18,099 | Jul 11, 2025 |
| Jul 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -878 | $0.00 | $0 | 27,450 | Jul 11, 2025 |
| Jul 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,440 | $0.00 | $0 | 20,859 | Jul 11, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.